167 related articles for article (PubMed ID: 38326699)
1. Correlation Analysis of Clinician- and Patient-Reported Outcomes Among Japanese Adults with Atopic Dermatitis.
Saeki H; Kataoka Y; Etoh T; Katoh N; Teramukai S; Tajima Y; Fujita H; Ardeleanu M; Arima K
Dermatol Ther (Heidelb); 2024 Feb; 14(2):533-543. PubMed ID: 38326699
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal course and phenotypes of health-related quality of life in adults with atopic dermatitis.
Schwartzman G; Lei D; Ahmed A; Chavda R; Gabriel S; Silverberg JI
Clin Exp Dermatol; 2022 Feb; 47(2):359-372. PubMed ID: 34623642
[TBL] [Abstract][Full Text] [Related]
4. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden.
Katoh N; Saeki H; Kataoka Y; Etoh T; Teramukai S; Takagi H; Tajima Y; Ardeleanu M; Rizova E; Arima K;
J Dermatol; 2019 Apr; 46(4):290-300. PubMed ID: 30756423
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate-to-severe atopic dermatitis: Two-year data from the ADDRESS-J disease registry.
Katoh N; Saeki H; Kataoka Y; Etoh T; Teramukai S; Takagi H; Fujita H; Ardeleanu M; Rizova E; Arima K;
J Dermatol; 2022 Sep; 49(9):903-911. PubMed ID: 35715964
[TBL] [Abstract][Full Text] [Related]
6. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
[TBL] [Abstract][Full Text] [Related]
11. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.
Iannone M; Tonini G; Janowska A; Dini V; Romanelli M
Curr Med Res Opin; 2021 Aug; 37(8):1295-1301. PubMed ID: 34027753
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.
Kimball AB; Delevry D; Yang M; Chuang CC; Wang Z; Bégo-Le-Bagousse G; Martins B; Wu E; Shumel B; Wang J; Sierka D; Chao J; Strober B
Dermatol Ther (Heidelb); 2023 Sep; 13(9):2107-2120. PubMed ID: 37552431
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
[TBL] [Abstract][Full Text] [Related]
14. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
[TBL] [Abstract][Full Text] [Related]
15. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
[TBL] [Abstract][Full Text] [Related]
16. Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the U.K. and the U.S.A.
Andersen L; Nyeland ME; Nyberg F
Br J Dermatol; 2020 May; 182(5):1176-1183. PubMed ID: 31437300
[TBL] [Abstract][Full Text] [Related]
17. Validity and reliability of Patient-Reported Outcomes Measurement Information System Global Health scale in adults with atopic dermatitis.
Schwartzman G; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY; Silverberg JI
J Am Acad Dermatol; 2021 Sep; 85(3):636-644. PubMed ID: 33484762
[TBL] [Abstract][Full Text] [Related]
18. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: A prospective observational study.
Chovatiya R; Lei D; Ahmed A; Chavda R; Gabriel S; Silverberg JI
Ann Allergy Asthma Immunol; 2021 Jul; 127(1):83-90.e2. PubMed ID: 33819616
[TBL] [Abstract][Full Text] [Related]
19. Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):180-187. PubMed ID: 32745300
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]